Q2 2025 Management View Steven O. Vondran, President and CEO, stated that "2025 continues to be a good year." He highlighted ...

Novo Nordisk's stock has dropped 21% after the company lowered its sales forecast and named Mike Doustdar as the new CEO.

Shipowners grapple with OPEC+ supply increases, tensions in the Middle East, and rising numbers of newbuildings.

The upgrade for emerging markets reflects a more optimistic outlook globally by the Fund, which nudged global GDP growth ...

Schneider adds that investors seem optimistic about American Tower due to stronger domestic organic growth heading into ...

Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 ...

Pharma giant Novo Nordisk A/S (NYSE:NVO) is plunging 21% to trade at a nearly three-year low of $54.27, after the company's ...

The IMF on Tuesday raised its global growth forecasts for 2025 and 2026 slightly, citing stronger-than-expected purchases ...

Discover AtriCure's standout Q2 2025 performance with 17% revenue growth, boosted by product innovation and international expansion.

The International Monetary Fund has revised India’s economic growth forecast upwards to 6.4% for both 2025 and 2026, citing a ...

Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO.

Sysco Corporation reports Q4 2025 financial growth with $21.1B in sales, innovative growth initiatives, and optimistic 2026 outlook.